Indian Hospira Plant Gets Extensive Form 483

Drug GMP Report
A A
Sterile injectables maker Hospira was hit with a new Form 483 containing nearly two dozen observations after FDA investigators followed up an October 2012 inspection that uncovered inadequate sanitization procedures at its Irungattukottai, India, manufacturing plant.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00